13.7% | Eli Lilly and Company, accessed April 23, 2025, How to Use, Dosing & Side Effects | Mounjaro (tirzepatide) - Eli Lilly, accessed April 23, 2025, Mounjaro (tirzepatide) Injection: The First and Only GIP and GLP-1 Receptor Agonist Approved for Type 2 Diabetes | Eli Lilly and Company, accessed April 23, 2025, Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight, accessed April 23, 2025, Why you're not losing weight on Zepbound
The honest answer is: partially
But its not a miracle drug
No insurance is required, and the medication is HSA/FSA eligible, making precision weight loss therapy accessible and predictable
However, anecdotal reports from patients and online communities suggest that some individuals do experience this symptom, particularly those achieving substantial weight loss